A single-arm, open, observational clinical study of selinexor combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed patients with extramedullary, plasma cell leukemia, or high-risk multiple myeloma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2022
This article has no abstract
Epistemonikos ID: ea32e346981e72df14ae309d4b1f8b420e34674c
First added on: Apr 08, 2025